Henry Schein Orthodontics Enhances Myofunctional Offerings with Froggymouth® Introduction
Henry Schein Orthodontics (HSO), the orthodontics division of Henry Schein, Inc., has announced the availability of Froggymouth®, an innovative myofunctional device designed to assist in the management of orofacial dysfunctions. Manufactured by Biotech Dental Smilers, the device is now accessible through Henry Schein Dental across the United States, marking a significant step in expanding HSO’s portfolio of clinically driven orthodontic solutions.
This addition reflects the company’s ongoing commitment to providing comprehensive treatment options that address not only structural dental concerns but also the underlying functional factors that can influence orthodontic outcomes. By incorporating Froggymouth into its offerings, HSO aims to support clinicians in delivering more holistic care, particularly in cases where dysfunctional oral habits contribute to malocclusion.
Addressing an Often Overlooked Component of Orthodontic Care
Zachary Meli, Vice President and General Manager at HSO, emphasized the importance of addressing functional issues alongside traditional orthodontic treatment. He noted that dysfunctional swallowing patterns are frequently underdiagnosed and undertreated, despite their significant role in influencing long-term treatment success.
Froggymouth is designed as a simple, passive device that integrates easily into patients’ daily routines. Its ease of use, combined with its foundation in published scientific research, makes it a valuable tool for clinicians seeking to enhance treatment outcomes. By making the device widely available through its distribution network, Henry Schein aims to ensure that more dental professionals can incorporate myofunctional therapy into their practices.
A Passive, Patient-Friendly Rehabilitation Approach
Unlike many traditional myofunctional therapies that require active patient participation through repetitive exercises, Froggymouth takes a passive approach to rehabilitation. The device is typically worn for just 15 minutes per day, often during sedentary activities such as watching television or using digital devices.
The mechanism of action is based on a structured four-step process:
- Inhibition of Dysfunctional Swallowing Habits – The device prevents habitual incorrect swallowing patterns.
- Saliva Accumulation – This creates a natural urge to swallow.
- Discovery of Physiological Swallowing – The body is encouraged to adopt a more natural swallowing mechanism.
- Automation of the Correct Pattern – With repeated use, the improved swallowing behavior becomes automatic.
Through consistent daily use, Froggymouth supports neuromuscular re-education, helping patients develop healthier tongue posture and oral function over time. This passive methodology is particularly beneficial for children and individuals who may struggle with compliance in more active therapy programs.
Scientific Foundation and Clinical Relevance
Froggymouth was developed in 2011 by Dr. Patrick Fellus, a French orthodontist specializing in pediatric and functional orthodontics at Robert Debré Hospital in Paris. The device is rooted in principles of orofacial functional rehabilitation and neurophysiology, drawing on established research in myofunctional therapy.
Its effectiveness is supported by peer-reviewed studies published in respected journals such as the European Journal of Pediatric Dentistry and Dentistry Journal. These studies highlight the role of functional therapy in improving oral habits and supporting orthodontic stability.
Integration with Active Orthodontic Treatments
One of the key advantages of Froggymouth is its compatibility with a wide range of orthodontic treatments. It can be used alongside clear aligner systems, including Smilers® aligner therapy, as well as traditional braces and correction techniques such as Sagittal First.
By addressing functional contributors to malocclusion during active treatment, clinicians can potentially enhance both the efficiency and durability of orthodontic results. The integration of Froggymouth into digital workflows, including the Smilers platform, further streamlines its use in modern orthodontic practices.
Clinical data also supports its effectiveness in combination therapies. In one study, 85.7% of patients treated with Carriere™ Motion® appliances alongside Froggymouth developed a correct swallowing pattern within approximately four months, demonstrating its potential to accelerate functional improvements.
Safety, Supervision, and Treatment Duration
Froggymouth is classified as a Class I medical device and must be prescribed and monitored by a qualified healthcare professional. Treatment duration varies depending on the patient’s condition but typically ranges between two and six months.
Because of its simplicity and short daily usage requirement, the device is designed to encourage high patient compliance, which is a critical factor in achieving successful outcomes in myofunctional therapy.
Availability and Access
Dental professionals can now browse and order Froggymouth devices and kits directly through the Henry Schein Dental website. The addition of this product underscores HSO’s broader mission to equip clinicians with tools that support both structural and functional aspects of orthodontic care.
For more information about Froggymouth and the complete range of solutions offered by Henry Schein Orthodontics, professionals are encouraged to visit the company’s official website.
A Step Toward More Comprehensive Orthodontic Care
The introduction of Froggymouth represents a meaningful advancement in the integration of myofunctional therapy into mainstream orthodontics. By addressing the functional behaviors that contribute to dental misalignment, clinicians can take a more preventive and sustainable approach to treatment.
As awareness of the importance of orofacial function continues to grow, tools like Froggymouth are likely to play an increasingly central role in improving patient outcomes. Henry Schein Orthodontics’ decision to include this device in its portfolio reflects a forward-looking strategy that prioritizes innovation, evidence-based practice, and comprehensive patient care.
About Henry Schein, Inc.
Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for health care professionals powered by a network of people and technology. With more than 25,000 Team Schein Members worldwide, the Company’s network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Our Business, Clinical, Technology, and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites.
Henry Schein operates through a centralized and automated distribution network, with a selection of more than 300,000 branded products and Henry Schein corporate brand products in our distribution centers.
A FORTUNE 500 Company and a member of the S&P 500® index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 34 countries and territories. The Company’s sales reached $13.2 billion in 2025 and have grown at a compound annual rate of approximately 11.0 percent since Henry Schein became a public company in 1995.
